Fall 9-1-2001

PHAR 574.01: Integrated Studies V

Michael P. Rivey
University of Montana, Missoula

Follow this and additional works at: https://scholarworks.umt.edu/syllabi

Let us know how access to this document benefits you.

Recommended Citation
https://scholarworks.umt.edu/syllabi/6208

This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.
(Draft #4 8-29) Pharmacy 552 & 595 B.S. : Therapeutics III (+) Fall 2001

Lectures: M-W-Th 1010-1100 Rm 114, Skaggs Building
F only 1010-1100 Rm 336, Skaggs Building
(note: joint lectures with Pharm.D class in SB114 or 117)
(note: 595 lectures on Weds 0910-1000 in SB 336)

Course Coordinator: Michael Rivey ===> M. Rivey
Instructors: Douglas Allington Office: 243-6796
Rose Macklin Community Hosp: 728-4100 ext. 7605
Cathy Bartels
Sarah Miller Pager: 329-6122
Gayle Cochran Home: 251-3369
Donna Beall Larry Dent
Lee Ann Bradley Vince Colucci
William Docktor Tim Stratton

Material and Resources
APhA: Handbook of Nonprescription Drugs
Medical Letter on Drugs & Therapeutics
Goodman & Gilman's Pharmacological Basis of Therapeutics
Boh Pharmacy Practice Manual
A medical dictionary

Optional Texts: Murphy: Clinical Pharmacokinetics pocket reference
Evans: Applied Pharmacokinetics
Young, Koda-Kimble: Applied Therapeutics
Hansten & Horn: Drug Interactions
Pagana & Pagana: Diagnostic & Lab Test Ref., or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.
Performance Objectives
Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:
--determine the necessity of drug therapy,
--when applicable, choose the proper drug and/or drug product for the situation.

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles.

Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to therapy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations

* To attend and participate in lecture sessions.

* To do assigned readings from the texts.

* To attend Integrated Studies conferences, prepare each case in advance, prepare to present a patient case, and participate in the discussion of all patient presentations.

* To perform satisfactorily on course quizzes and lecture examinations.
GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each 300 points
Final exam (comprehensive, multiple choice) 130 points
(100 pts comprehensive, 30 pts over last 6 lectures)
Topic quizzes: 8 quizzes graded on 10 pts each Bonus pts > 75%
TOTAL POINTS FOR COURSE 430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic. Quizzes will occur before topic lectures and will test understanding of basic concepts in the reading assignments. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. QUIZ on syllabus indicates a quiz will be given for the overall topic at start of the given lecture and will concern only assigned reading for that day. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. Scoring: Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & APhA books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The "make-up" requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:
3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your student colleagues have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They do not appreciate any “side” conversations while the instructor is lecturing. They do appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we encourage questions and relevant discussion.
## Therapeutics III 552 B.S. & Phar 595 supplemental course: Lecture Syllabus

<table>
<thead>
<tr>
<th>Week</th>
<th>Date</th>
<th>Topic</th>
<th>Instructor</th>
<th>Reading</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept</td>
<td>5W</td>
<td>Introduction/ Liver disease (9AM SB336)</td>
<td>MPR (595)</td>
<td>35, 38</td>
</tr>
<tr>
<td></td>
<td>5W</td>
<td>Liver disease</td>
<td>MPR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6Th</td>
<td>Liver disease</td>
<td>MPR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7F</td>
<td>Renal disease/ (10AM in SB 114)/ QUIZ</td>
<td>DRA</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>10M</td>
<td>Renal disease</td>
<td>DRA</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>12W</td>
<td>Hypertension</td>
<td>LAD (595)</td>
<td>JNC-6 download</td>
</tr>
<tr>
<td></td>
<td>12W</td>
<td>HTN</td>
<td>LAD</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>13Th</td>
<td>HTN</td>
<td>LAD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14F</td>
<td>Pain Management (10 AM SB114)</td>
<td>LAB</td>
<td>56, OTC 18</td>
</tr>
<tr>
<td></td>
<td>17M</td>
<td>Pain mgmt (11AM SB117)</td>
<td>LAB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19W</td>
<td>Headache (11AM SB 117)/ QUIZ</td>
<td>DB</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>20Th</td>
<td>Congestive Heart Failure</td>
<td>VJC</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>21F</td>
<td>Headache (10AM SB 114)</td>
<td>DB</td>
<td>OTC 25</td>
</tr>
<tr>
<td></td>
<td>24M</td>
<td>CHF</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25T</td>
<td>Career Fair</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26W</td>
<td>CHF</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>27Th</td>
<td>Digoxin kinetics</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28F</td>
<td>Coronary Artery Disease</td>
<td>VJC</td>
<td>12</td>
</tr>
<tr>
<td>Oct</td>
<td>1M</td>
<td>CAD</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3W</td>
<td>Arthritis (11AM SB 117)/ QUIZ</td>
<td>MPR</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>4Th</td>
<td>Arthritis</td>
<td>MPR</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>5F</td>
<td>Arthritis (note!! 11AM SB 117)</td>
<td>MPR</td>
<td>OTC pp 71-2, OTC5</td>
</tr>
<tr>
<td></td>
<td>5F</td>
<td>Test 1 at 1-3 PM in SB 114; through Dig PK</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8M</td>
<td>Gout (11AM SB 117)</td>
<td>MPR</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>10W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10W</td>
<td>Hyperlipidemia</td>
<td>LAD</td>
<td>ATP III download</td>
</tr>
<tr>
<td></td>
<td>11Th</td>
<td>Hyperlipidemia</td>
<td>LAD</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>12F</td>
<td>Contraception (10AM SB114)/ QUIZ</td>
<td>DB</td>
<td>OTC 8</td>
</tr>
<tr>
<td></td>
<td>15M</td>
<td>Contraception</td>
<td>DB</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>17W</td>
<td>Contraception</td>
<td>DB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17W</td>
<td>Dysrhythmias</td>
<td>VJC</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>18Th</td>
<td>off day- no class</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19F</td>
<td>off; ASP-MRM meeting in Seattle</td>
<td>VJC</td>
<td></td>
</tr>
</tbody>
</table>
Oct  22M  Menopause (11AM SB 117)/ QUIZ  GAC  78
24W  Drug Literature Evaluation  CLB (595)
24W  Menopause (11 AM SB 117)  GAC
25Th  Dementia  GAC  61
26F  Osteoporosis (10 AM SB 114)  GAC  82, OTC 419-20
29M  Osteoporosis (11AM SB 117)  GAC
31W  Drug Literature Evaluation  CLB (595)
31W  Obstructive Airways Disease/ QUIZ  DRA  24
(11AM SB 117)

Nov  1Th  Theophylline kinetics  DRA
2F  OAD (10AM SB 114)  DRA  25, OTC 10
2F  Test 2 at 1-3 PM n SB 114; through osteoporosis
5M  Oncology overview  CLB  DiPiro pp.2013-41  7W
Oncology overview  CLB (595)
7W  Thromboembolic Disease (11AM SB 117)  MPR  17
8Th  TED  MPR
9F  Stroke/ (10AM SB 114)/ QUIZ  MPR  18
12M  VETERANS DAY HOLIDAY
14W  Nausea & vomiting  LAB (595)  33, OTC 5
15W  Seizure dx/ QUIZ  DRA  52
15Th  Seizure disorders  DRA
16F  Anticonvulsant kinetics  DRA
19M  Fluid & electrolytes  SJM  DiPiro pp 890-902
21W  OFF; TRAVEL DAY
22Th  THANKSGIVING HOLIDAY
23F  “  ”
26M  F&E  SJM  pp 902-16
28W  Biostatistics overview  TPS (595)
28W  Nutrition  SJM
29Th  Thyroid disorders  MPR  71
30F  Diabetes mellitus/ QUIZ  LRM  70

Dec  3M  DM  LRM
5W  Biostatistics overview  TPS (595)
5W  DM tests  LRM  OTC 39
6Th  Anxiety/sleep disorders  WJD  67,69, OTC 24
7F  test 3 at 1-3 PM in SB 114; through nutrition
552-Ther III & Phar 595, continued

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Instructor</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10M</td>
<td>Attention deficit disorder</td>
<td>WJD</td>
<td>DiPiro pp. 1046-49</td>
</tr>
<tr>
<td>12W</td>
<td>Biostatistics overview</td>
<td>TPS (595)</td>
<td></td>
</tr>
<tr>
<td>12W</td>
<td>CLASS EVALUATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13Th</td>
<td>Depression/ QUIZ</td>
<td>WJD</td>
<td>65</td>
</tr>
<tr>
<td>14F</td>
<td>Depression</td>
<td>WJD</td>
<td></td>
</tr>
</tbody>
</table>

Phar 552-BS Final: test 4, 130 pts comprehensive multiple choice NAPLEX/PSAP format
Phar 595 Final: see below; biostatistics questions added to Final

NOTE: class will meet at 10AM or 11AM (if meeting together with Pharm.D. class) on days throughout the semester

Pharmacy 595: supplemental course

Phar 595: Course is 1-hour Wednesday session to supplement Ther-III and cover other topics not in B.S. curriculum in an overview fashion. It is graded course

Schedule: merged to above syllabus (weekly on Weds at 0910-1100 in SB 336)

Instructors: various Therapeutics instructors
Cathy Bartels
Tim Stratton

Grading in Phar 595:

6/14 of course grade: project in Drug Literature Evaluation
3/14 of course grade: biostatistics questions on Final Exam (add-on questions)
5/14 of course grade: grade obtained in Ther. Phar 552 course
Integrated Studies Phar 574

I. Conference topics

Tuesday 0910-1100 SB335 Rivey
Tuesday 0910-1100 SB337 Colucci

week of:

**September**
- 3M no conference
- 10M Liver disease case
- 17M Hypertension case
- 24M Headache/pain management

**October**
- 1M Digoxin kinetics
- 8M J-club for ½ of class; **service learning work session**
- 15M OTC cases
- 23M Contraception
- 29M **service learning update**: J-club for other ½ of class

**November**
- 5M **SEMINARS**
- 12M OAD case
- 19M **off week- holiday week**
- 26M TED case

**December**
- 3M OTC cases
- 10M Evaluation/ Diabetes case

**Seminar**: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.